Product
Linvoseltamab
Aliases
REGN5458
Name
Linvoseltamab
Target
BCMA×CD3
FDA Approved
No
Ema approved
Status
0
7 clinical trials
2 abstracts
5 indications
Indication
Smoldering Multiple MyelomaIndication
Systemic Light Chain AmyloidosisIndication
Multiple MyelomaIndication
Relapsed Refractory Multiple MyelomaClinical trial
Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple MyelomaStatus: Not yet recruiting, Estimated PCD: 2032-02-26
Clinical trial
A Phase 1/2 Study of Linvoseltamab in Patients With Relapsed or Refractory Systemic Light Chain AmyloidosisStatus: Not yet recruiting, Estimated PCD: 2028-08-26
Clinical trial
Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2032-05-04
Clinical trial
Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple MyelomaStatus: Recruiting, Estimated PCD: 2035-11-02
Clinical trial
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)Status: Recruiting, Estimated PCD: 2032-12-26
Abstract
LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.Org: Karmanos Cancer Institute, Ziekenhuis Netwerk Antwerpen Stuivenberg, Regeneron Pharmaceuticals, Inc.,
Clinical trial
Phase 2 Study of Linvoseltamab in Patients With Smoldering Multiple Myeloma at High Risk of Progression to Multiple MyelomaStatus: Recruiting, Estimated PCD: 2032-12-19
Clinical trial
Immuno-consolidation for Newly Diagnosed Multiple Myeloma Using Lack of MRD Negativity After Initial cOmbination Therapy to Pursue Deeper Responses With Linvoseltamab ANd Delay TransplantStatus: Not yet recruiting, Estimated PCD: 2027-06-30